Back to search results

Observational Study for Suspected Lung Cancer

This study, called "Interception for Suspected Lung Cancer," is looking at how well robotic biopsies can provide genetic information for people with suspected or high-risk lung cancer. It's an observational study, meaning you won't receive a new treatment, but researchers will gather information from your medical care. The goal is to see if enough good quality samples can be collected for genetic testing (sequencing) and to build a database for future research. You can join if you are 18 or older, scheduled for a bronchoscopy (a procedure to look at your airways and lungs), have a moderate to high risk of lung cancer or suspected metastatic (spread) disease, and can provide blood or saliva samples and archived tissue. The study aims to get at least 80% adequate samples for genetic testing.

Study design
This is an observational study with a planned enrollment of 40 participants. It is not specified if it is randomized or blinded.
What's involved
You will receive genetic counseling and education, provide blood or saliva samples, and allow researchers to use previously collected tissue samples and review your medical records. The duration of your participation is not specified.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, assessing sample adequacy, is measured up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06482073

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~250 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent of samples adequate for sequencing
Measured over Up to 2 years

Conditions

Lung Carcinoma
Metastatic Malignant Neoplasm in the Lung

Explore related trials

Lung Carcinoma

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Janani S. Reisenauer, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Thoracic Research
[email protected]
507-293-0807
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject age 18 years and older
Subject is scheduled/was scheduled for a bronchoscopy or surgical resection as part of standard of care
Subject with a moderate to high risk of lung cancer based on clinical demographic and radiologic information or with suspected metastatic disease
Ability to provide blood or saliva sample
Ability to provide archived tissue
Subject is able to understand and adhere to study requirements and able to provide informed consent

Exclusion

Individuals who have situations that would limit compliance with the study requirements
Institutionalized (i.e. federal medical prison)
Pregnant
Prior germline genetic testing with a 40+ multi-gene panel AND/OR prior somatic tissue (250+ gene) testing utilizing the tissue from the bronchoscopy or surgical resection

What this trial measures

  • Percent of samples adequate for sequencingUp to 2 years

    Assessed based on the number of tissue samples determined to be adequate for WES (Whole Exome Sequencing)/WT (wild-type) sequencing.